Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab in mild to moderate Alzheimer's disease (ApoE4 carriers)
NCT00676143Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jan 2008
- Primary completion
- Oct 2012
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bapineuzumab 0.5 mg/kg with Placebo (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 78 weeks and Disability Assessment for Dementia at 78 weeks. Started Jan 2008; status: terminated.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00676143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676143.